Amphora Discovery Corporation To Present Posters On Promising Results From AKT And Target Tyrosine Kinase (TTK) Programs At AACR-NCI-EORTC International Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 8 /PRNewswire/ -- Amphora Discovery Corporation today announced that abstracts containing promising data from Amphora's preclinical AKT and Targeted Tyrosine Kinase (TTK) programs have been accepted for poster presentation at the AACR-NCI-EORTC International Conference in Philadelphia, Pennsylvania November 14 -18, 2005.

Details are as follows: - Presentation Time: November 15th 12.30 - 2.30 pm.; 5.30 - 7.30 pm Poster Session A Title: Multi-Targeted Tyrosine Kinase Inhibitors of FLT3 + cKIT + PDGFR for the Treatment of Hematological Malignancies and Solid Tumors. Poster A264 - Amphora will present data on several proprietary series of inhibitors that are highly selective for the combination of FLT3 + cKIT + PDGFR over a broad panel of 96 enzymes. These inhibitors have been rapidly optimized and demonstrate low nanomolar potency in blocking proliferation in a leukemia cell line. - Presentation Time: November 17th 12.30 - 2.30 pm.; 5.30 - 7.30 pm Session C Title: Is One Enough? - Development of Highly Selective AKT1 Inhibitors as a Targeted Therapy for Cancer. Poster C147 - Amphora will present the latest data on potent compounds that are highly selective for the AKT1 isoform. These compounds display nanomolar inhibitory activity and are >100-fold selective over AKT2, AKT3, and 96 other enzyme targets. Cellular assays addressing apoptosis, proliferation, and phosphorylation of downstream substrates with the AKT1 selective inhibitors will be shown. About Amphora

Amphora is a biopharmaceutical company with a pipeline of internally discovered product candidates that address oncology and inflammation indications. The company is engaged in the discovery and development of superior, highly-selective, small molecule medicines for both large and small markets. By leveraging its robust and proprietary chemical-biological database, Amphora is pursuing a next generation drug discovery strategy. Amphora's preclinical programs include AKT1, p38, and TRPV1 as well as partnered programs. For more information, please visit the company's web site at www.amphoracorp.com.

CONTACT: Tracy Thompson, Corporate Communications of Amphora,+1-919-287-6177, or Tracy.Thompson@amphoracorp.com

Web site: http://www.amphoracorp.com//